Company Description
NeurogesX is paving the way for treating neuropathic pain, a chronic, often debilitating pain involving both the peripheral and central nervous...
Key NeurogesX Financials
| Company Type | Public - NASDAQ (GM): NGSX Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | -- |
More NeurogesX Financials (7 pages)
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs....
Read more about NeurogesX's competition across multiple industries
Top NeurogesX Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
NeurogesX Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| President, CEO, and Director | Anthony DiTonno | Network | E-mail |
| CFO | Stephen F. Ghiglieri | Network | E-mail |
| VP Commercial Operations and Business Development | Michael Markels | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current NeurogesX News
- PRODRUGS AND METHODS OF MAKING AND USING THE SAME [PCT Biblio Info] (17 Jun 2008 12:23:00 EDT)
- NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference [Pain & Central Nervous System Week] (16 Jun 2008 00:01:00 EDT)
- Briefing.com: Hourly In Play (R) - 23:00 ET [Briefing.com] (10 Jun 2008 23:00:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.







